Vaccitech plc

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

91864C107

SEDOL

N/A

CIK

0001828185

www.vaccitech.co.uk

LEI:

FIGI: BBG00ZZPCP09

VACC

Vaccitech plc

GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology

PROFILER

NAME

Vaccitech plc

ISIN

US91864C1071

TICKER

VACC

MIC

XNAS

REUTERS

VACC.OQ

BLOOMBERG

VACC US

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Fri, 15.11.2024

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Research & Analysis

Fri, 15.11.2024

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with

Research & Analysis

Wed, 06.11.2024

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Research & Analysis

Thu, 08.08.2024

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

Research & Analysis

Wed, 12.06.2024

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Research & Analysis

Thu, 06.06.2024

Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.

Research & Analysis

Mon, 13.05.2024

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Vaccitech plc

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Newsletter